|
Highlights from DDW 2014; HCV Treatment Regimens
(Preview)
A Healio.com article regarding information presented at: Digestive Disease Week 2014; May 3-6, 2014; Chicago Re-treatment with Sofosbuvir, Interferon effective in GT 2 or 3 Telaprevir (Incivek) showed greater SVR, cost-effectiveness than Boceprevir (Victrelis) among HCV patients ...
|
Tig
|
2
|
714
|
|
|
|
|
Information On Clinical Trials For Those With Liver Transplants and HCV
(Preview)
I know several people who have had liver transplants and have hepatitis C. They are trying to find out more about the new direct-acting antivirals (sofosbuvir, ledipasvir,etc.) and about the clinical trials for those with liver transplants and HCV. I would truly appreciate any information you c...
|
lauralou57
|
2
|
682
|
|
|
|
|
Update On Gilead Financials
(Preview)
I wanted to share this link which all of my friends have been sending me all day: http://www.gilead.com/news/press-releases/2014/4/gilead-sciences-announces-first-quarter-2014-financial-results
|
lauralou57
|
0
|
741
|
|
|
|
|
Excellent easily understandable course on Hep C--includes info on HCC--Cirrhosis Etc
(Preview)
Ran across this in my search for info on HCC after treatment. Really found it to be VERY informative. Screening and Diagnosis of Hepatitis C Infection - Hepatitis C Online SuziQ
|
suziq
|
2
|
975
|
|
|
|
|
CDC is investigating possible occupational exposure
(Preview)
FYI: "The CDC is investigating possible occupational exposure to HIV, hepatitis B virus, hepatitis C virus and Mycobacterium tuberculosis among workers at a human nontransplant anatomical donation center in Arizona" CDC: Infection exposure possible at nontransplant anatomic...
|
Tig
|
0
|
634
|
|
|
|
|
ViralEd Independent Review of the 49th Annual EASL
(Preview)
Lengthy (90 min) but informative eSymposium discussing key data presented at the recently concluded EASL in London. Email address required to view. Topics include various study data (Pearl, Sapphire, Ion, Cosmos and others), treatment of cirrhotics, whether to use riba or not, re-treatment af...
|
OldenSlow
|
2
|
902
|
|
|
|
|
NHS England agrees limited funding for Sofosbuvir ahead of `NICE` approval
(Preview)
Very good news for the most severely affected Hep C patients in England - well done our NHS! Press Release, 16th April: NHS England has approved an £18.7 million investment in a new drug for the treatment of hepatitis C.Around 500 patients with acute liver failure, and/or awaiting liver transplant...
|
Cinnamon Girl
|
0
|
1030
|
|
|
|
|
Price of a Cure
(Preview)
This article is provided by Healio.com. Some of their articles are open to review and some require a simple and free registration. Their email newsletters make registration worth doing. The following article addresses the conversation we've all been following, the cost of treatment. It offers s...
|
Tig
|
1
|
660
|
|
|
|
|
HCV Next publication
(Preview)
Another Healio.com specialty publication exclusively focused on HCV. Offers a multitude of articles and reports dealing with our favorite subject HCV. Again, this publication may require a free registration to view the complete report or website. It's a very worthwhile registration. HCV Next...
|
Tig
|
0
|
672
|
|
|
|
|
Viral Hepatitis Presentations in Pediatrics
(Preview)
Interesting article on hepatitis in pediatrics, but it shares similarities in all age groups. Good read! Viral Hepatitis Presentations in Peds. Tig
|
Tig
|
0
|
616
|
|
|
|
|
VA, California Panels Urge Costly Hepatitis C Drugs For Sickest Patients
(Preview)
"Doctors should consider expensive new hepatitis C drugs for patients with advanced liver disease, including those awaiting transplants, but ask most others to wait for drugs in development, the Department of Veterans Affairs said Wednesday." "A California panel made si...
|
OldenSlow
|
2
|
817
|
|
|
|
|
Great Info on the London Liver conference VERY COMPLETE on all new combos
(Preview)
Hepatitis C - DAAs: continuing the advance towards a cure. This is a great informational report on all the new drugs presented at the London Liver Conference that took place last week. Select the 2014 conference and scroll down all the presentations. Even Merck presented. Looks like I was one of on...
|
suziq
|
0
|
812
|
|
|
|
|
European liver specialists recommend `mix-and-match` approach to new hepatitis C drugs
(Preview)
The European Association for the Study of the Liver has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals EASL is also encouraging European physicians to combine products from diff...
|
Cinnamon Girl
|
0
|
692
|
|
|
|
|
2ND Article on Ledipasvir and Sofosbuvir for Treatment NAIVE HCV Genotype 1 Infection
(Preview)
Hey All This is the trials results for Treatment Naive Hep C Geno Type 1 This is the 2ND Great article that Gilead and most of the Trials site Doctors have collaborated on that was released at the EASL Conference in London this week-end and also was released as a important article in The New England Jour...
|
Matt Chris
|
1
|
664
|
|
|
|
|
New Chinese herbal medicine has significant potential in treating Hepatitis C
(Preview)
http://virtualpressoffice.easl.eu/new-chinese-herbal-medicine-has-significant-potential-in-treating-he...
|
Matt Chris
|
2
|
823
|
|
|
|
|
Sovaldi complaints go global
(Preview)
Hi Everyone, I was watching the news this morning and FOX News had a report delivered on their Sunday Housecall segment on the new treatment opportunity with Sovaldi. I wanted to share their video segment but am unable to find it. But I did find this information via links on their website and thought yo...
|
Tig
|
1
|
633
|
|
|
|
|
Why Hepatitis C is Vastly Underreported
(Preview)
A good summation of the challenges faced in dealing with the underreporting of HCV. The Underreporting of HCV
|
OldenSlow
|
0
|
681
|
|
|
|
|
Gilead/Express Scripts: Who is really the greedy one?
(Preview)
An investor's take on the Gilead/Express Scripts war. Link requires subscription for full article, so pasted below.[url=http://seekingalpha.com/article/2132933-express-scripts-trying-to-shame-gilead-into-reducing-sovaldi-price-who-is-really-the-greedy-one]Seeki...
|
OldenSlow
|
3
|
1322
|
|
|
|
|
WHO (World Health Organisation) joins clamour to make new Hep C pills affordable
(Preview)
article...[url]http://www.reuters.com/article/2014/04/09/healt...
|
Cinnamon Girl
|
0
|
543
|
|
|
|
|
Gilead says has discounted hepatitis C drug for some health plans
(Preview)
"(Reuters) - Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview..." [url]http://www.reuters.com/article/2014/03/29/us-gilead-hepatitis-idUSBR...
|
OldenSlow
|
7
|
1078
|
|
|
|
|
Gilead Wash. DC study, 100% cure rate 12 wk. & 6 wk
(Preview)
http://www.hcvadvocate.org/news/newsLetter/2014/advocate0414.html#1-- Edited by madd...
|
maddie
|
11
|
1534
|
|
|
|
|
April 2014 HCV Advocate Newsletter
(Preview)
From the HCV Advocate website.This month`s issue includes details of the new drug studies presented at The Conference on Retroviruses and Opportunistic Infections (CROI), from Abbvie, BMS, BMS/Janssen, and Gilead. CROI:14 was recently held in Boston, MA, and this year there were quite a few pr...
|
Cinnamon Girl
|
0
|
610
|
|
|
|
|
Phase 3 trials evaluating Simeprevir and Sofosbuvir have been initiated.
(Preview)
Press Release, 2 April 2014, Stockholm, Sweden - Medivir AB today announces that two phase III trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic geno...
|
Cinnamon Girl
|
4
|
1048
|
|
|
|
|
2014 Chronic Hep C: Treat Now or Wait?
(Preview)
Here is a slide presentation that may help provide those making this decision, treat now or wait. Hepatitis C: Treat Now or Wait?
|
Tig
|
3
|
687
|
|
|
|
|
Daclatasvir/Olysio Combo Effectively Treats Hep C Genotype 1b
(Preview)
Daclatasvir/Olysio Combo Effectively Treats Hep C Genotype 1b A combination of low-dose daclatasvir and Olysio (simeprevir) cured a relatively high proportion of people with genotype 1b of hepatitis C virus (HCV), but just two thirds of a small group of genotype 1as. Findings from the LEAGUE-...
|
Tig
|
2
|
1027
|
|
|
|
|
HCV and HIV Vaccine Research
(Preview)
http://www.healio.com/hepatology/chronic-hepatitis/news/online/%7Ba80b5165-93ef-4373-8c39-ec11541cb833%7D/hcv-hiv-vaccine-research-focuses-on-indirect-dendritic-cell-stimulation
|
Tig
|
0
|
562
|
|
|
|
|
Infectious Disease News Updates
(Preview)
Here are some updates that I think you all might find interesting. The first in the group deals with patient adherence. One of the biggest causes of premature treatment failure was due to the pill burden. The new treatments are so much better in that respect. When I was on treatment recently, taking th...
|
Tig
|
1
|
766
|
|
|
|
|
European Medicines Agency Validates Gilead's Marketing Application for Ledipasvir/Sofosbuvir
(Preview)
"...Although accelerated assessment of this investigational fixed-dose combination could shorten EMA's review time by approximately two months, it does not guarantee a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) or final approval by the Europe...
|
OldenSlow
|
2
|
726
|
|
|
|
|
Gilead offers Egypt new hepatitis C drug at 99 pct discount
(Preview)
(Reuters) - "Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price. While the drug will still cost $900 for a 12-week course of treatment, that is a fraction of...
|
OldenSlow
|
8
|
1220
|
|
|
|
|
Sovaldi/Olysio Survey Data
(Preview)
From the Decision Resources Group March 19, 2014 "Cost is the leading prescribing barrier for both Olysio and Sovaldi. Although most surveyed prescribers did not indicate major payer obstacles, many non-prescribers reported experiencing reimbursement obstacles, suggesting that re...
|
OldenSlow
|
3
|
1286
|
|
|
